Moderna Capitalizes On Its Headstart In COVID-19 Vaccines
Leaked List Shows Premium Price Secured With EU
The US biotech has booked orders of nearly 500 million doses for its COVID-19 vaccine, and a leaked price list from Europe shows it has secured a premium price ahead of all its rivals, including Pfizer/BioNTech.
You may also be interested in...
While demand for COVID-19 vaccines will be huge for the next two years, only those players with major manufacturing and commercial infrastructures in place will play a big role.
The FDA granted emergency authorization for Moderna's mRNA-1273 following a 17 December advisory committee vote in its favor. There have also been more supply deals and approvals in Asia.
Early results from its novel antiviral are encouraging, but demonstrating life-saving qualities in a short window of time will be tricky.